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Abstract
Background: Depressive disorders are the most common form of mental disorders in community and health care
settings. Unfortunately, the treatment of Major Depressive Disorder (MDD) is far from satisfactory. Vagus nerve
stimulation (VNS) is a relatively new and promising physical treatment for depressive disorders. One particularly
appealing element of VNS is the long-term benefit in mood regulation. However, because this intervention involves
surgery, perioperative risks, and potentially significant side effects, this treatment has been limited to those patients
with treatment-resistant depression who have failed medication trials and exhausted established somatic
treatments for major depression, due to intolerance or lack of response.
This double-blinded randomized clinical trial aims to overcome these limitations by introducing a novel method of
stimulating superficial branches of the vagus nerve on the ear to treat MDD. The rationale is that direct stimulation
of the afferent nerve fibers on the ear area with afferent vagus nerve distribution should produce a similar effect as
classic VNS in reducing depressive symptoms without the burden of surgical intervention.
Design: One hundred twenty cases (60 males) of volunteer patients with mild and moderate depression will be
randomly divided into transcutaneous vagus nerve stimulation group (tVNS) and sham tVNS group. The treatment
period lasts 4 months and all clinical and physiological measurements are acquired at the beginning and the end
of the treatment period.
Discussion: This study has the potential to significantly extend the application of VNS treatment for MDD and
other disorders (including epilepsy, bipolar disorder, and morbid obesity), resulting in direct benefit to the patients
suffering from these highly prevalent disorders. In addition, the results of this double-blinded clinical trial will shed
new light on our understanding of acupuncture point specificity, and development of methodologies in clinical
trials of acupuncture treatment.
Trials registration: Clinical Trials. ChiCTR-TRC-11001201 http://www.chictr.org/cn/
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Major depressive disorder (MDD) is the fourth leading
cause of disability worldwide [1], and is projected to be-
come the second leading cause of disability worldwide
by the year 2020 [2,3]. Despite the critical need, current
treatments for these disorders are far from satisfactory
[1,3] due to high non-response rate to treatments, high
relapse rates, and frequent intolerable side effects. The
etiology and pathogenesis of depression in MDD is not
clear; however, it is generally believed that the cause of
major depressive disorder is a combination of brain
chemistry, family history, and psychosocial environment.
Vagus nerve stimulation (VNS) is a relatively new
FDA-approved somatic treatment for treatment-resistant
depression (TRD) that can produce significant and clin-
ically meaningful antidepressant effects [1,4-6]. Studies
also indicate that VNS may provide long-term sustained
benefits [1,5,7], which is particularly compelling given
the highly recurrent nature of MDD [3]. However, the
involvement of surgery, perioperative risks, and poten-
tially significant side effects have limited this treatment
only to those patients who have been treated for depres-
sion in the past but have failed to respond to at least 4
prescribed medications and/or established somatic treat-
ment options such as electroconvulsive therapy (ECT)
for MDD [8].
This double-blinded randomized clinical trial aims to
overcome these limitations of VNS by testing the effi-
cacy of a novel method of transcutaneous vagus nerve
stimulation (tVNS) to treat MDD. The rationale for
using tVNS is that anatomical studies have shown that
the ear is the only place on the surface of the human
body where there is afferent vagus nerve distribution
[9,10]. Thus, direct stimulation of the afferent nerve
fibers on the ear should produce an effect similar to
classic VNS in reducing depressive symptoms without
the burden of surgical intervention [11].
Additionally, as an important branch of acupuncture,
auricular acupuncture has been widely used to treat various
disorders including MDD by stimulating points on the ear.
Thus, we believe the results of this study will also enhance
our understanding of acupuncture mechanisms, shedding
new light on acupoint specificity.
Methods and design
Trial design
This study is a randomized, multicenter, double blind
clinical trial with two treatment groups (tVNS and sham
tVNS). Please see flow chart (Figure 1) for more details
regarding the clinical procedures. The clinical endpoints
are assessed by blinded independent observers. The cen-
tral randomization system is used to assign patients to
the tVNS or sham tVNS treatment groups. All proce-
dures are performed by the Clinical Evaluation Center at
the China Academy of Chinese Medical Sciences
(CACMS) in Beijing. The Ethics committee of Institute
of Acupuncture and Moxibustion, CACMS approved the
experiment procedure.
Setting
Investigators are conducting the trial in four hospitals in
Beijing, China. These four hospitals are: Guang An Men
Hospital, China Academy of Chinese Medical Sciences;
Huguosi TCM Hospital, Beijing University of TCM;
Acupuncture Hospital, China Academy of Chinese
Medical Sciences.
Blinding
As a double-blinded trial, both study physicians/
investigators and patients are blinded to treatment
group (tVNS versus sham tVNS). To ensure that both
investigators and patients remain blinded, two carbon-
impregnated silicone electrodes are fixed to one ear
clamp (Figure 2). Only one of the electrodes; however,
is connected to the electrical lead (wire) imbedded in
the clamp in order to keep the operation of the study
double blind. In the tVNS group, the upper electrode
was wired to the transcutaneous electrical nerve stimu-
lator (TENS) while in the sham tVNS group the lower
electrode is inactively wired to the TENS.
Both the physician’s and the patient’s blindness to the
mode of treatment are assessed after completion of all
post-treatment measurements by asking each individual
to guess the treatment modality they received given
three options, “real tVNS”, “sham tVNS” or “uncertain”.












Figure 1 Flow chart of the clinical trial.
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Study population
Patients with mild or moderate MDD are recruited for
the trial. ICD-10 Classification of Mental and Behavioral
Disorders are used for diagnosis of MDD. Patients who
voluntarily provide informed consent and meet inclu-
sion/exclusion criteria are enrolled in this study. Inclu-
sion and exclusion criteria include:
Inclusion criteria
1. Patient meets ICD-10 diagnosis standard: mild (2
typical + 2 other core symptoms), moderate (2
typical+3 other core symptoms).
2. Patient is 16–70 years of age
3. Patient stopped taking anti-depressive medication or
other psychiatric medications 2 weeks before the
intervention started.
4. Patient is educated beyond junior high school, in
order to understand the scales.
5. Patient has exhibited symptoms for at least 2
months, and no longer than 2 years.
Exclusion criteria
1. Patients with current addiction to drugs
2. Patients with severe depression or suicidal thoughts
3. Patients with severe medical disorders
4. Patients with poor compliance
Recruitment procedures
The investigators recruit patients with mild or moderate
depressive symptoms using advertising and by sending
flyers to the four hospitals involved in the study. After
passing a pre-screening, potentially eligible patients




Location The points for tVNS are located in the auricu-
lar concha area where there is rich vagus nerve branch
distribution (Figure 2).
Intervention procedure Patients take a seated position
or they lay on their side. After the stimulation points are
disinfected according to standard practice, ear clips are
attached to the ear area (auricular concha) that will be
stimulated. Stimulation parameters include: 1) density
wave adjusted to 20Hz, with less than 1ms wave width;
and 2) 1mA current turned on. The intensity is adjusted
based on the tolerance of the patient. Each treatment
lasts for 30 minutes and is carried on twice a day, 5 days
per week for the duration of the treatment period (12
weeks).
Sham tVNS treatment
Location The stimulation points for sham tVNS are
located at the superior scapha (outer ear margin mid-
point), where there is no vagus nerve distribution
(Figure 2).
Intervention procedure All procedures performed in
the sham tVNS treatment group are identical to the pro-
cedures for the verum tVNS group.
Choice of endpoints
All endpoints are measured at week 0 and week 10. The
endpoints include the 24-item Hamilton Depression
Figure 2 Locations and the stimulation electrodes on the auricular surface. Red spots indicate the locations for transcutaneous auricular
vagus nerve stimulation (tVNS) and blue spots indicate the locations for sham tVNS. The left figure shows the two tVNS points being in the
innervation area of the auricular branch of vagus nerve (green). The right figure indicates the clip/electrode used in the study. To achieve the
design of double-blind, two paired electrodes were fixed to one ear clamp. But only one of them was connected with the wire that was
imbedded in the clamp in order to keep the operation of double-blind. In the tVNS group, the upper electrodes are wired to the machine while
in the sham tVNS group the lower electrodes are wired.
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pression Rating Scale (HAM-D-17), Self-rating Anxiety
Scale (SAS), Self-rating Depression Scale (SDS), electro-
cardiogram rate, breathing rate, and skin conduction re-
sponse. Similar to previous studies [12,13], the primary
outcome is the categorical classification of treatment re-
sponse. We are interested in comparing the difference in
treatment response rate between the two groups as mea-
sured by HAM-D-24, where treatment response is
defined as a 50% or greater reduction in HAM-D-24
scores following a 10-week treatment.
In addition, previous studies [14-17] suggest that
expectations for symptom relief can significantly influ-
ence the response to medications, acupuncture, and pla-
cebo. Thus, before the first treatment, patients are asked
to rate on a scale how much they expect the treatment
will relieve their symptoms, from “complete relief” to
“do not work at all”.
Sample size calculation and statistical analysis
Sample size
We present here our power analysis for the primary out-
come only. Since this is a novel therapy, we used the
data from a previous non-controlled pilot study on
treatment-resistant MDD in senior patients [18] to cal-
culate the power. The primary outcome measure is the
categorical classification of response; we define the treat-
ment response as a 50% or greater reduction in HAM-
D-24 scores following treatments. From a previous proof
of concept study [18], the response rate in the tVNS
group is 39%; assuming a 20% dropout rate, with 60 pa-
tient in each group, we will have 80% power to detect a
difference of 25% or greater in response rate between
the tVNS and the sham tVNS group based on a chi
square test at a 0.05 significance level.
Statistical analysis
In this study, the primary outcome measure is the cat-
egorical classification of treatment response. We define
the treatment response as a 50% or greater reduction in
HAM-D-24 scores following treatments. Response rates
across the two groups will be compared with the chi
square (x
2) test.
Additionally, we will also use the HAM-D-24 score as
continuous variable and apply a regression model to
compare the different between two treatment groups.
More specifically, in the model, the dependent variable
is post-treatment HAM-D-24 score, the independent vari-
able is treatment mode (tVNS versus sham tVNS), and
covariances will include pre-treatment HAM score, age
and gender. Similar analyses will also be performed in
other clinical and physiological outcome measurements.
Data safety monitoring
Independent data safety monitoring board members will
meet every 6 months or as needed. Participants who
show persistent worsening symptoms during the course
of a clinical trial or develop unstable psychiatric symp-
toms (e.g., suicidality, homicidality, psychosis) will be
withdrawn from the study and will be referred for ap-
propriate treatment immediately.
According to the following classifications, a safety
monitoring board will review and rate adverse events to
determine whether to suspend the test condition.
Level 1: Security, without any adverse reactions.
Level 2: Safe, and have mild adverse reaction, do not
need any treatment can continue to treatment.
Level 3: There are security issues; there is a moderate
adverse reaction, after treatment may continue to
treatment.
Level 4: Because of adverse reactions, terminate this
research.
All adverse events will be reported to the Human
Research Committee promptly in accordance with
guidelines.
Discussions
Depression, with serious medical, social and economic
consequences, represents a significant burden to both
patients and society. Unfortunately, reports suggest that
despite the progress that has been made in pharmaco-
logic and psychological treatments, many MDD patients
only partially benefit or do not benefit at all [1,3]. Add-
itionally, pharmacologic treatments often have a high
rate of relapse and intolerable side effects, which further
the call for new treatment of MDD.
VNS is a relatively new FDA-approved somatic treat-
ment for depressive disorders [1,4-6] and may provide
long-term sustained benefits [1,5,7]. The limitations and
adverse events related to VNS are quite obvious, includ-
ing the involvement of surgery, perioperative risks, and
potentially significant side effects such as hoarseness,
throat pain, coughing, dyspnea, paresthesia, and muscle.
Thus, VNS treatment is limited only to those patients
who have exhausted the standard somatic treatments for
MDD due to intolerance or lack of response [8].
The underlying mechanism of antidepressant action
using VNS is not fully understood. Hypotheses are based
on the anatomy and function of the vagus nerve, which
is implicated in mood control [19]. It is known that the
vagus nerve is a mixed nerve composed of about 80% af-
ferent fibers. It is speculated that antidepressant effects
of VNS are attributed partially to the projection of affer-
ent fibers to the nucleus tractus solitaries, which is fur-
ther connected directly and indirectly with brain
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parabrachial nucleus, the locus coeruleus, the amygdala,
hypothalamus, insula, thalamus, orbitofrontal cortex,
and other limbic regions responsible for mood and anx-
iety regulation [5,9].
This clinical trial aims to overcome these limitations
by introducing a novel method of stimulating superficial
branches of the vagus nerve to treat MDD. The evidence
supporting the feasibility of this trial includes: 1) two
proofs of concept, non-controlled, clinical trials demon-
strated that tVNS can be used as an effective treatment
for treatment-resistant MDD in both senior patients [18]
and in epilepsy patients [20], another important indica-
tion of the VNS; 2) An fMRI study [21] showed that
tVNS at specific ear regions can produce significant
fMRI signal decreases, which is similar to the brain ac-
tivity changes produced by VNS [22-24]. It is important
to note that the same stimulation at ear regions without
vagal supply could not evoke similar fMRI signal
changes. In addition, only after tVNS, psychometric as-
sessment of research subjects revealed significant im-
provement in well-being; and 3) two animal studies
[25,26] demonstrated that stimulation of the certain
areas of the ear with vagus nerve supplies can evoke fir-
ing of the vagus nerve and produce relatively specific
physiological changes (e.g. decreased arterial pressure,
heart rate, and intragastric pressure). Thus, results from
both human and animal studies have endorsed the ra-
tional of the treatments.
In a previous study in senior patients with resistant
MDD, Xu and colleagues [18] found that compared with
the drug only group, drug plus electroacupuncture
stimulation at a point in the ear where the vagus nerve
is distributed can produce greater HAM-D score reduc-
tion and more good responders. However, the lack of an
accepted control group significantly limited the inter-
pretation of the study. In this protocol, we have included
an active control group (sham tVNS), and used a
double-blinded design, which could significantly enhance
the quality of the clinical trial.
Compared with traditional VNS, tVNS has the advan-
tage of being low cost, safe and non-invasive. Thus, it
can be used on patients with mild to moderate MDD. If
this study is successful, the results will significantly ex-
tend the application of VNS treatment to MDD and
other disorders (including epilepsy, bipolar disorder, and
morbid obesity) and will result in direct benefit to the
patients suffering from these highly prevalent disorders.
Additionally, we believe that this study will also en-
hance our understanding of acupuncture mechanisms.
As an important branch of acupuncture treatment and
with extensive application in past decades, auricular
acupuncture, with specific indication of different ear
acupoints, remains a mystery. The tVNS treatment for
M D Dp r o v i d e sau n i q u ea n g l ea sw e l la sam o d e lt o
investigate the biological basis underlying acupoint
specificity.
Finally, to blind both the investigator and patient, we ap-
plied two pairs of carbon-impregnated silicone electrodes,
only one of which was wired to give electrical output; thus,
neither patients nor physicians know whether they received
real or sham tVNS. This double-blinded design can signifi-
cantly improve the quality of the trial and will shed new
light on the development of methodologies in clinical trials
of acupuncture treatment.
In summary, in this clinical trial, we are evaluating the
efficacy of tVNS in mild and moderate MDD patients
using a randomized and double-blinded design. The suc-
cess of the trial will significantly improve the application
of this promising new method.
Trial status
The first participants were included on May 18, 2011.
There are 49 participants recruited until the point when
this paper was submitted on September, 2012.
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